Axxess Pharma, Inc. Enters $35 Billion Arthritis Market (AXXE)

Axxess Pharma, Inc. Enters $35 Billion Arthritis Market Acquiring Canadian Distribution Rights of Unique Pain Relief Medication FORTEX Rubbing Oil(R)

FORTEX Is Sold in 20 Countries Worldwide and Will Now Enter the Canadian Market Where Over 4 Million Canadian Citizens Are Experiencing Arthritis and Soft Tissue Injuries

MARKHAM, ON, Dec 15, 2010 (MARKETWIRE via COMTEX) -- Axxess Pharma Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce the acquisition of FORTEX Rubbing Oil(R) from Actium Pharmaceuticals, Inc. The acquisition now provides Axxess Pharma quick entry into the $35 billion arthritis market. FORTEX is currently sold in 20 countries worldwide. Under the terms of the acquisition, Axxess Pharma now has exclusive distribution rights throughout Canada.

FORTEX is a topical medication requested by physicians on a daily basis. The medication provides rapid and lasting relief of pain associated with musculoskeletal conditions, such as arthritis and soft tissue injuries. Once applied to the skin, FORTEX is readily absorbed directly down to the site of pain. Topical medications such as FORTEX are rapidly expanding due to patients no longer choosing to experience painful side effects caused by their oral pain medication. These side effects are well documented by medical professionals and patients and range from mild, severe and sometimes fatal reactions.

Locally acting topical medications such as FORTEX have the potential to exhibit a safer side effect profile as they deliver the drug directly to the pain site through the skin, resulting in lower levels of the active ingredient entering the blood stream compared to oral medications. Axxess Pharma anticipates strong sales due to demand in the Canadian market.

According to the Arthritis Society of Canada, over 4 million Canadians are diagnosed with arthritis resulting in over 8.8 million physician visits per year for arthritis and related conditions. These numbers are anticipated to continue to increase due to the aging population and obesity.

"I am pleased with Axxess Pharma's business relationship, and the prospects it brings for FORTEX in the Canadian market. FORTEX possesses a unique position for this market. The product works and allows clinicians and patients a cost-effective way to manage musculoskeletal pain and discomfort. This is accomplished by enabling the replacing, decreasing, or adding to, oral-NSAID therapy, which is costly and comes with risks," said Michel Lockhart, representative for Actium Pharmaceuticals.

For more information, please contact Investor Relations at (973) 351-3868.

About Axxess Pharma, Inc.:

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.